VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/255,364 for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast).
The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company has been issued corresponding patents in Japan and China, with applications pending in Europe and Canada.
The Chronic Kidney Disease Market size is estimated at USD 84.85 billion in 2025, and is expected to reach USD 109.95 billion by 2030, at a CAGR of 5.32% during the forecast period (2025-2030).1
Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction (UUO) mouse model.
Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms.
“Algernon’s intellectual property strategy for our innovative drug repurposing programs continues to be very successful,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “It is increasingly more difficult to confirm novelty and receive a method of use patent with the advent of AI being used as a drug discovery tool. It is an important achievement and provides substantial protection for Repirinast and its use as a treatment for kidney disease.”
Preclinical Data
Data from the UUO study demonstrated that clinically relevant doses resulted in statistically significant improvements in the reduction in fibrosis as measured by Sirius Red staining over untreated controls:
Telmisartan (3 mg/kg), a positive control, reduced fibrosis by 32.6% (p
